Support from the U.S. Department of Defense Will Accelerate Progress on Vaccine Candidate for COVID-19, IAVI Says

IAVI announced today the award of US$26.7M from the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense (DoD) to support IAVIs recombinant vesicular stomatitis virus (rVSV) vectored SARS-CoV-2 vaccine candidate.